SUMO-1 (PIC-1/Sentrin-1/Smt3c) (1-5), Smt3a (SUMO-2, Sentrin-3) (6), and Smt3b (SUMO-3, Sentrin-2) (6, 7) are highly homologous to ubiquitin and are thus referred to as ubiquitin-like proteins (Ubls). The homology between Smt3a and Smt3b is 95%, and the homology of Smt3a and Smt3b with SUMO-1 is 45% and 47%, respectively. They conjugate covalently to their target proteins (sumoylation) in a manner analogous to ubiquitination. At least in vitro, sumoylation is carried out by two enzymatic steps using a heterodimeric E1 enzyme (Sua1 (Aos1)/Uba2) (8-11) and the E2 enzyme Ubc9 (12, 13). These Ubls have been shown to conjugate to proteins such as RanGAP1 (14-16), , Sp100 (17), IκBα (21), p53 (22, 23) and so on through an isopeptide linkage between a glycine residue in the carboxyl terminus of them and the ε-amino group of a lysine residue of the target protein. The sumoylation plays multiple functional roles in protein targeting, stabilization, and transcriptional activation. SUMO-1 modification of RanGAP1 results in the transfer of the protein from the cytoplasm to the nuclear pore complex. In the case of PML and Sp100, sumoylation leads to their subnuclear localization in the so-called PML nuclear bodies (NBs). Sumoylation of IκBα acts antagonistically to ubiquitination, and the modified IκBα is resistant to degradation. In addition, the SUMO-1 modification of p53 was shown to enhance the transcriptional activity of p53.
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SUMO-1 (PIC-1/Sentrin-1/Smt3c) (1-5), Smt3a (SUMO-2, Sentrin-3) (6) , and Smt3b (SUMO-3, Sentrin-2) (6, 7) are highly homologous to ubiquitin and are thus referred to as ubiquitin-like proteins (Ubls). The homology between Smt3a and Smt3b is 95%, and the homology of Smt3a and Smt3b with SUMO-1 is 45% and 47%, respectively. They conjugate covalently to their target proteins (sumoylation) in a manner analogous to ubiquitination. At least in vitro, sumoylation is carried out by two enzymatic steps using a heterodimeric E1 enzyme (Sua1 (Aos1)/Uba2) (8) (9) (10) (11) ) and the E2 enzyme Ubc9 (12, 13) . These Ubls have been shown to conjugate to proteins such as RanGAP1 (14) (15) (16) , PML (17) (18) (19) (20) , Sp100 (17) , IκBα (21), p53 (22, 23) and so on through an isopeptide linkage between a glycine residue in the carboxyl terminus of them and the ε-amino group of a lysine residue of the target protein. The sumoylation plays multiple functional roles in protein targeting, stabilization, and transcriptional activation. SUMO-1 modification of RanGAP1 results in the transfer of the protein from the cytoplasm to the nuclear pore complex. In the case of PML and Sp100, sumoylation leads to their subnuclear localization in the so-called PML nuclear bodies (NBs). Sumoylation of IκBα acts antagonistically to ubiquitination, and the modified IκBα is resistant to degradation. In addition, the SUMO-1 modification of p53 was shown to enhance the transcriptional activity of p53.
In the conjugation system, a glycine residue in the carboxyl terminus of SUMO-1, Smt3a, or Smt3b is essential (7, 14, 15) . However, the carboxyl terminal residue of these proteins is not glycine. Therefore, the protein must be processed by a carboxyl terminal hydrolase to produce a glycine residue in the carboxyl terminus prior to conjugation to the target proteins. A SUMO-1/Smt3 isopeptidase, which cleaves the linkage between SUMO-1, 4 Smt3a, or Smt3b and target protein in the conjugate (desumoylation), is also thought to exist. Budding yeast Ulp1 was the first identified of this kind of protease (24), which had both activities of carboxyl terminal hydrolase and isopeptidase toward Smt3. Ulp1 is essential for cell viability and cell-cycle progression, and a temperature-sensitive mutant of Ulp1 arrests cells at the G2/M phase at the nonpermissive temperature. Another budding yeast Smt3 deconjugating enzyme, Ulp2/Smt4, has been identified (25). Deletion of ULP2 results in a variety of phenotypic abnormalities.
These findings suggested that SUMO-1/Smt3-specific protease plays a significant role in the regulation of SUMO-1/Smt3-mediated cellular processes.
In mammalian cells, three SUMO-1/Smt3-specific isopeptidases have been isolated and characterized, so far (26, 28, 29). One of them, SMT3IP1, which we isolated by use of the yeast two-hybrid screening using Smt3b as bait, was located exclusively in the nucleolus during interphase (26). This enzyme bound to Smt3a and Smt3b, but not to SUMO-1, in both the yeast two-hybrid system and in vitro binding assays. However, the enzyme could liberate SUMO-1, Smt3a, or Smt3b from SUMO-1/RanGAP1, Smt3a/RanGAP1 or Smt3b/RanGAP1, respectively, in vitro.
But its carboxyl terminal hydrolase activity was very weak when SUMO-1-, Smt3a-, or Smt3b-Myc-His6 was used as substrate.
By EST database searching using carboxyl terminal catalytic domains of SMT3IP1, we found several cDNAs encoding putative SUMO-1/Smt3-specfic proteases.
Here, we describe the isolation and characterization of one of these SUMO-1/Smt3-specfic proteases, which we call SMT3IP2/Axam2. It showed both SUMO-1/Smt3 hydrolase and isopeptidase activities, and was 5 localized almost exclusively in the cytoplasm. Furthermore, this protein is a homologue of rat Axam (27), the latter of which binds to Axin (30) and promotes β-catenin degradation.
EXPERIMENTAL PROCEDURES
Isolation of SMT3IP2 cDNA -By using mouse expressed sequence tag (EST) database searching with the tBLASTn program for genes encoding proteins having sequence homology with the carboxyl terminal catalytic domains of SMT3IP1, we identified three EST clones (GenBank accession No. AI664083, AI152880 and AI390987), which overlapped partially with each other. Based on these EST sequences, a cDNA fragment was amplified by the reverse transcriptase polymerase chain reaction (RT-PCR) method using total RNA from mouse MC3T3E1 cells. The resulting PCR product was labelled with [α-32 P]dCTP by random priming and used as a probe for screening a mouse MC3T3E1 cDNA library in λgt10 (6 10 5 plaques), which was kindly provided by Dr. Kiyoshi Nose, Showa University, Japan, to obtain a full-length cDNA. One positive cDNA clone was obtained and sequenced to confirm that it was the full-length murine SMT3IP2/Axam2 cDNA. In the isopeptidase assay, GST-RanGAP1 was conjugated by biotinylated SUMO-1, Smt3a or Smt3b in vitro as described (9) . The GST-SMT3IP2/Axam2 was purified as described above. The substrate immobilized on the glutathione-Sepharose 4B beads (500 ng of protein) was 
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RESULTS
cDNA Cloning of SUMO-1/Smt3-specific Isopeptidase SMT3IP2/Axam2
-Earlier we isolated a SUMO-1/Smt3-specific protease and named it SMT3IP1 (26). This enzyme was found to be distantly related to yeast Ulp1 and AI390987), partially overlapped each other, suggesting that they were originated from the same cDNA. Based on these EST sequences, a cDNA fragment was amplified by PCR, sequenced, and used as probe to screen a cDNA library. One positive clone was isolated. The cDNA insert was separated into two fragments by EcoRI, subcloned in pBluescript SK+, and sequenced. This cDNA contained a 1626-bp open reading frame encoding a protein of 541 amino acids with a predicted molecular weight of 62 kDa (Fig. 1A) . We named this protein SMT3IP2/Axam2, because of the characteristics of this protein described below. The catalytic domains in the carboxyl terminal region of SMT3IP2/Axam2 were very similar to those of 10 other SUMO-1/Smt3-specific proteases, but the amino-terminal part of SMT3IP2/Axm2 was quite different from that of the other enzymes. The cysteine, histidine, and aspartic acid residues in the catalytic domains, which are characteristic of the SUMO-1/Smt3-specific protease, were conserved.
Sequence analysis also indicated that amino acid sequence of the SMT3IP2/Axam2 was almost identical to that of the previously reported rat
Axam (GenBank Accession number AF260129) (27) and human SENP2
(GenBank Accession number AF151697), although its amino-terminal region was shorter than that of them (Fig. 1B) . SMT3IP2/Axam2 cDNA had 67 base pairs, where a stop codon was detected in frame, that were not contained in either the rat Axam or human SENP2 sequence (see sequence underlined in Fig. 1A) . Also, the first two bases (GT) and the last two bases (AG) in this extra sequence corresponded to the bases in the intronexon border. These data suggest that SMT3IP2/Axam2 may be alternatively spliced from the same gene corresponding to rat Axam or human SENP2.
To check whether this mRNA is expressed indeed in mouse tissues or culture cells, we conducted RT-PCR using total RNA from mouse brain, heart, thymus, and Balb/c 3T3 cells. The PCR products from all tissues and cells tested were sequenced and were identical to this SMT3IP2/Axam2 cDNA (data not shown), suggesting that SMT3IP2/Axam2 is a major transcript in mouse cells.
In Vitro Interaction of SMT3IP2/Axam2 with Ubiqutin-like Proteins -
To demonstrate an interaction between SMT3IP2 and ubiquitin-like proteins, we expressed ubiqutin-like proteins in Escherichia coli as glutathione S-transferase (GST) fusion products. After they had been mixed and incubated with COS-7 cell lysates expressing GFP-SMT3IP2/Axam2, glutathione-Sepharose 4B resin was added to the mixture to capture the 11 GST-fusion proteins. As shown in Figure 2 , SMT3IP2/Axam2 bound efficiently to GST-Smt3a or GST-Smt3b, but not to GST-SUMO-1, GSTNedd8, GST-ubiquitin, or GST alone. This feature of SMT3IP2/Axam2 is similar to that of SMT3IP1.
In Vitro Enzyme Assay of SMT3IP2 -To test whether or not SMT3IP2
indeed had SUMO-1/Smt3-specific protease activity, we prepared and purified the recombinant protein and assayed its activity. The GST-tagged SMT3IP2/Axam2 expressed in E. coli and purified by use of glutathione Sepharose 4B had the ability to cleave SUMO-1, Smt3a, and Smt3b from SUMO-1/RanGAP1, Smt3a/RanGAP1, and Smt3b/RanGAP1 conjugate, respectively (Fig. 3A) . This enzyme activity was inhibited by treatment of SMT3IP2/Axam2 with N-ethylmaleimide (NEM) prior to incubation with the substrates, indicating that the reaction required an active sulfhydryl residue(s). When the cysteine 500 residue, which was suspected to be essential for the activity, was mutated to alanine, the mutant C500A did not show the activity. This result confirmed that this cysteine residue must be the catalytically active one. Furthermore, to determine whether SMT3IP2 also had carboxyl terminal hydrolase activity toward SUMO-1, Smt3a, or Smt3b in vitro, we prepared GST-SUMO-1-Myc-His6, GST-Smt3a-MycHis6, GST-Smt3b-Myc-His6, and GST-Nedd8-Myc-His6 for use as substrates (Fig. 3B) . As shown in Figure 3C , SMT3IP2 could cleave the carboxyl terminal moiety of GST-SUMO-1-Myc-His6, GST-Smt3a-MycHis6 or GST-Smt3b-Myc-His6, and the enzyme seemed to cleave Smt3a
and Smt3b more preferably than SUMO-1 (Fig. 3C, lane 3) . The enzyme did not cleave GST-Nedd8-Myc-His6 or GST-ubiquitin-His6-Myc6
proteins. These results indicate that SMT3IP2/Axam2 had both SUMO-1/Smt3-specific isopeptidase and carboxyl terminal hydrolase activities.
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Isopeptidase Activity in Transfected Cells -To check the isopeptidase activity in intact cells, we co-transfected HeLa cells with the cDNA of either wild-type or C500A mutant SMT3IP2/Axam2 and FLAG-tagged SUMO-1, Smt3a or Smt3b. As shown in Figure 4 , FLAG-tagged SUMO-1, Smt3a or Smt3b could be conjugated to cellular target proteins. When wildtype GFP-SMT3IP2/Axam2 was overexpressed in the cells, all three conjugates almost disappeared (Fig. 4, lanes 2, 5, and 8) . Conversely, when the sole GFP moiety or the mutant C500A was overexpressed in cells, the three conjugates were still present. These results indicate that SMT3IP2/Axam2 could also hydrolyze the linkage between SUMO-1, Smt3a, or Smt3b and target protein in the conjugate in intact cells and that SMT3IP2/Axam2 functions toward these three conjugates without any detectable differences in this assay system.
Subcellular Localization of SMT3IP2/Axam2
-To check the localization of the enzyme in cells, we transfected SW480 cells with GFP-fused fulllength SMT3IP2/Axam2, and examined the localization of the protein by fluorescence microscopy. As shown in Figure 5 , when GFP-SMT3IP2/Axam2 alone was expressed in SW480 cells, it was located predominantly throughout the cytoplasm and in cytoplasmic vesicles surrounding the nucleus (Fig. 5A) . In contrast, when GFP-SMTIP2/Axam2
and Myc-Axin were co-expressed in SW480 cells, each protein seemed to be located in the same cytoplasmic vesicles (Fig. 5B ). This pattern of localization is similar to that observed previously when rat Axam and Axin were co-expressed in SW480 cells (27).
Effects of Mutant SMT3IP2/Axam2 Expression on Destabilization of -
catenin -Overexpression of rat Axam in SW480 cells reduced the level of β-catenin protein in SW480 cells (27). So we also checked the effect of 13 SMT3IP2/Axam2 on the stabiliy of β-catenin. As shown in Figure 6 , when the wild-type enzyme was expressed in SW480 cells, the level of endogenous cytoplasmic β-catenin protein was reduced (Fig. 6B) .
Therefore, the amino-terminal sequence of SMT3IP2/Axam2, which is different from that of rat Axam, was not required for this effect.
Furthermore we examined whether the protease activity of SMT3IP2/Axam2 was necessary for the reduction in the amount of β-catenin in the cells. When the protease activity-negative C500A mutant was expressed in SW480 cells, β-catenin also disappeared in the transfected cells (Fig. 6C) . Furthermore when the 1-352 mutant, which does not have the catalytic domain of the enzyme, was expressed in the cells, β-catenin also disappeared in the transfected cells (Fig. 6D) . These results indicate that the protease activity of SMT3IP2 is not required for the destabilization of β-catenin in this transfection assay.
DISCUSSION
We found a previously unknown murine SUMO-1/Smt3-specific isopeptidase and named it SMT3IP2/Axam2. This enzyme was shown to be 
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